A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03637491

Recruitment Status : Terminated (Available clinical data has shown limited anti-tumor activity and reaching target study drug dose levels may not be feasible.)

First Posted : August 20, 2018

Last Update Posted : July 23, 2021

Sponsor:

Information provided by (Responsible Party):

Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	December 3, 2020
Actual Study Completion Date :	February 2, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020 Jun 30;48(3):1101-1108. doi: 10.1042/BST20191092. Review.

To Top